Compare Adaptive Biotechnologies Corp (ADPT) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs FTAI Aviation Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while FTAI Aviation Ltd trades at $213.44 (market cap $23.33B). The key difference: FTAI Aviation Ltd is far larger — about 7× Adaptive Biotechnologies Corp's market cap, and FTAI Aviation Ltd pays a 0.66% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FTAI | |
|---|---|---|
Market Cap | $3.33B | $23.33B |
Sector | Health | Industrials |
52-Week High | $22.37 | $310.04 |
52-Week Low | $10.24 | $109.76 |
Enterprise Value | $3.19B | $26.37B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FTAI Aviation trades at $241.54, down 2.63% amid a bearish technical signal, though it remains supported by strong profitability with a 34.99% gross margin and 226.91% ROE. Recent earnings have missed expectations, but revenue growth is projected to rise from $2.51B in 2025 to $2.8B in 2026. Positive news includes a strategic collaboration for Boeing 737-800 freighters and a $0.45 dividend announcement.
The outlook is mixed: robust analyst consensus (100% buy ratings) and innovation in data center power solutions offer upside, but high valuations (P/E 48.11) and consecutive earnings misses pose risks. Investors should weigh growth potential against execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
